Quizartinib Becomes SOC Option in Newly Diagnosed AML With FLT3 ITD Mutation
Quizartinib added to induction and consolidation chemotherapy and continued as a single agent for up to 36 cycles improves the overall survival of adults with FLT3 ITD mutated AML.
North Carolina United States Harryp Erba Division Of Hematologic Malignancies Meeting Of The Society Hematologic Oncology Leukemia Program
Source: targetedonc.com